Will Gilead reclaim its throne in the HCV drug market?

By Lee, Tak-Sun | translator Alice Kang

22.10.22 06:00:45

가나다라 0

Epclusa to be released with reimbursement starting next month, targets market leader Abbvie’s ‘Mavyret’

Can be used in all hep C genotypes like Mavyret... treatment period is longer but the price cheaper

Fierce competition is being expected in the hepatitis C (HCV) treatment market with the launch of Gilead’s new treatment which is priced at a lower level than the current market leader.

With the new product, Gilead is aspiring to reclaim the former glory that it had enjoyed dominating the market with Sovaldi.

According to industry sources on the 21st, Gilead Science Korea’s HCV treatment ‘Epclusa Tab (velpatasvir+sofosbuvir) and ‘Vosevi Tab (velpatasvir+sofosbuvir+voxilarprevir)’ will receive health insurance reimbursement from the 1st of next month.

The insurance price ceiling for Epclusa and Vosevi was set at KRW 117,030 and KRW 120,836, respectively.

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)